JavaScript is disabled. Please enable to continue!
Services >> Efficacy >> Metabolic / Endocrine

Examine therapeutic activity against a large set of in vivo metabolic models

Sidebar Image

With today's high caloric diets and sedimentary life style, increasing attention has been focused on remedying associated metabolic disorders, naming obesity and diabetes.  In early stages, these issues manifest in metabolic syndrome, a complex disease which is characterized by obesity, insulin resistance, pre-diabetic fasting glucose levels, fatty liver, and low HDL cholesterol levels. Left untreated, metabolic disorders can greatly increase the risk of stroke, type II diabetes, and cardiovascular disease.

Eurofins Pharma Discovery Services offers a complete list of qualified models for metabolic disorder, including Type I (induction by streptotozocin) and Type II diabetes models. The type I models allow examination of agents acting on insulin-independent pathways and affording end organ protection from diabetes, while the Type II models are conventional wildtype or genetic variants (db/db, ob/ob or ZDF) used with or without modified test diets to explore the impact of pharmacological agents on glucose metabolism and/or obesity.  Diabetic complications in humans include organ-specific microvascular damage with sequelae such as nephropathy, and we offer a panel of chronic kidney disease models, as well as models of acute and chronic hepatic injury.

We are able to expertly provide outcome measure of glucose tolerance or insulin tolerance test, as well as plasma lipid profile and measurements of serum insulin, glucagon, leptin, adiponectin, free fatty acid, cytokines, and other relevant biomarkers.  Our in vivo testing expertise can help bring your drug from the discovery phase all the way to clinical trials.

Advantages of Metabolic studies with Eurofins:

  • >40 therapeutically relevant models, including:
    • Food intake
    • Cholesterol
    • Glucose
    • Estrogen / androgen function  
    • Renal function
    • Renal and hepatic injury
  • Models are qualified in a dose-dependent manner with approved benchmark positive controls
  • Experienced running combination studies
  • Companion services can monitor blood or organ exposure and biomarker analysis for PK/PD assessment